This is a prospective , randomized , multicenter , investigator-initiated trial to evaluate the 12-month effectiveness of isovolemic hemodilution ( IH ) with prompt versus deferred intravitreal injections ( IVI ) of ranibizumab 0.5 mg for the treatment of macular edema secondary to early central retinal vein occlusion ( CRVO ) .